1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Pantarhei Bioscience BV - Product Pipeline Review - 2015

Pantarhei Bioscience BV - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 34 pages

Pantarhei Bioscience BV - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Pantarhei Bioscience BV - Product Pipeline Review - 2015’, provides an overview of the Pantarhei Bioscience BV’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pantarhei Bioscience BV’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Pantarhei Bioscience BV including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pantarhei Bioscience BV’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Pantarhei Bioscience BV’s pipeline products

Reasons to buy

- Evaluate Pantarhei Bioscience BV’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pantarhei Bioscience BV in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pantarhei Bioscience BV’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pantarhei Bioscience BV and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pantarhei Bioscience BV
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Pantarhei Bioscience BV and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Pantarhei Bioscience BV - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Pantarhei Bioscience BV Snapshot 5
Pantarhei Bioscience BV Overview 5
Key Information 5
Key Facts 5
Pantarhei Bioscience BV - Research and Development Overview 6
Key Therapeutic Areas 6
Pantarhei Bioscience BV - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Pantarhei Bioscience BV - Pipeline Products Glance 15
Pantarhei Bioscience BV - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Pantarhei Bioscience BV - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Pantarhei Bioscience BV - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Pantarhei Bioscience BV - Drug Profiles 19
(prasterone + estradiol acetate + progesterone) 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
(oxytocin + estrogen) 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
esterol 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
BLACE 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
T-2 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Pantarhei Bioscience BV - Pipeline Analysis 26
Pantarhei Bioscience BV - Pipeline Products by Target 26
Pantarhei Bioscience BV - Pipeline Products by Route of Administration 27
Pantarhei Bioscience BV - Pipeline Products by Molecule Type 28
Pantarhei Bioscience BV - Pipeline Products by Mechanism of Action 29
Pantarhei Bioscience BV - Recent Pipeline Updates 30
Pantarhei Bioscience BV - Dormant Projects 31
Pantarhei Bioscience BV - Locations And Subsidiaries 32
Head Office 32
Other Locations and Subsidiaries 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List of Tables
Pantarhei Bioscience BV, Key Information 5
Pantarhei Bioscience BV, Key Facts 5
Pantarhei Bioscience BV - Pipeline by Indication, 2015 7
Pantarhei Bioscience BV - Pipeline by Stage of Development, 2015 8
Pantarhei Bioscience BV - Monotherapy Products in Pipeline, 2015 9
Pantarhei Bioscience BV - Combination Treatment Modalities in Pipeline, 2015 10
Pantarhei Bioscience BV - Partnered Products in Pipeline, 2015 11
Pantarhei Bioscience BV - Partnered Products/ Combination Treatment Modalities, 2015 12
Pantarhei Bioscience BV - Out-Licensed Products in Pipeline, 2015 13
Pantarhei Bioscience BV - Out-Licensed Products/ Combination Treatment Modalities, 2015 14
Pantarhei Bioscience BV - Phase III, 2015 15
Pantarhei Bioscience BV - Phase II, 2015 16
Pantarhei Bioscience BV - Phase I, 2015 17
Pantarhei Bioscience BV - Preclinical, 2015 18
Pantarhei Bioscience BV - Pipeline by Target, 2015 26
Pantarhei Bioscience BV - Pipeline by Route of Administration, 2015 27
Pantarhei Bioscience BV - Pipeline by Molecule Type, 2015 28
Pantarhei Bioscience BV - Pipeline Products by Mechanism of Action, 2015 29
Pantarhei Bioscience BV - Recent Pipeline Updates, 2015 30
Pantarhei Bioscience BV - Dormant Developmental Projects,2015 31
Pantarhei Bioscience BV, Other Locations 32

List of Figures
Pantarhei Bioscience BV - Pipeline by Top 10 Indication, 2015 7
Pantarhei Bioscience BV - Pipeline by Stage of Development, 2015 8
Pantarhei Bioscience BV - Monotherapy Products in Pipeline, 2015 9
Pantarhei Bioscience BV - Combination Treatment Modalities in Pipeline, 2015 10
Pantarhei Bioscience BV - Pipeline by Top 10 Target, 2015 26
Pantarhei Bioscience BV - Pipeline by Top 10 Route of Administration, 2015 27
Pantarhei Bioscience BV - Pipeline by Top 10 Molecule Type, 2015 28
Pantarhei Bioscience BV - Pipeline Products by Top 10 Mechanism of Action, 2015 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Mitogen Activated Protein Kinase Kinase Kinase 5 (Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ...

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Growth Hormone Secretagogue Recepto ...

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2016

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.